<DOC>
	<DOCNO>NCT00006102</DOCNO>
	<brief_summary>Phase II trial study effectiveness rebeccamycin analogue treat child solid tumor non-Hodgkin 's lymphoma . Drugs use chemotherapy use different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>Rebeccamycin Analogue Treating Children With Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response child solid tumor non-Hodgkin 's lymphoma treat rebeccamycin analogue . II . Determine maintain plasma concentration least 5 Âµg/mL drug patient . III . Determine toxicity drug patient . IV . Determine pharmacokinetics drug patient . OUTLINE : This multicenter study . Patients solid tumor stratify accord tumor histology ( neuroblastoma v Ewing 's sarcoma [ close accrual 5/19/03 ] /peripheral primative neuroectodermal tumor [ PNET ] v osteosarcoma [ close accrual 5/19/03 ] v rhabdomyosarcoma v non-Hodgkin 's lymphoma v solid tumor ) . Patients CNS tumor stratify accord tumor histology ( medulloblastoma/PNET v ependymoma v brainstem glioma v CNS tumor ) . Patients receive rebeccamycin analogue IV 1 hour day 1 . Treatment continue every 21 day total 16 course absence disease progression unacceptable toxicity . Patients follow monthly 1 year , every 2 month 2 year , every 6 month 1 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor Neuroblastoma Ewing 's sarcoma/peripheral primitive neuroectodermal tumor ( PNET ) ( Ewing 's sarcoma close accrual 5/19/03 ) Osteosarcoma ( close accrual 5/19/03 ) Rhabdomyosarcoma Other extracranial solid tumor CNS/brain tumor : Medulloblastoma/PNET Ependymoma Brainstem glioma Other CNS tumor Histological verification may waive brainstem glioma classic optic glioma , biopsy recommend OR Histologically cytologically prove nonHodgkin 's lymphoma Refractory standard treatment curative therapy available Measurable disease PATIENT CHARACTERISTICS : Age : 21 time original diagnosis Performance status : Karnofsky 50100 % patient 10 year age Lansky 50100 % patient age 10 Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count great 1,000/mm^3 Platelet count great 75,000/mm^3 Hemoglobin great 8.0 g/dL Hepatic : Bilirubin normal age SGPT le 2.5 time upper limit normal Amylase normal Lipase normal Renal : Creatinine normal age OR Glomerular filtration rate least 60 mL/min Other : No concurrent uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Recovered prior immunotherapy Chemotherapy : At least 6 week since prior nitrosourea recover Recovered prior chemotherapy No two prior chemotherapy regimen Endocrine therapy : CNS tumor patient receive dexamethasone must stable decrease dose least 2 week prior study entry Radiotherapy : At least 6 week since prior extend radiotherapy recover No prior total body irradiation Surgery : Prior radiosurgery allow Other : No concurrent use follow food medication : Grapefruit juice Erythromycin Azithromycin Clarithromycin Rifampin analogues Fluconazole Ketoconazole Itraconazole Cimetidine Cannabinoids ( marijuana dronabinol ) Leukotriene inhibitor ( e.g. , zafirlukast zileuton ) No concurrent anticancer investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>intraocular retinoblastoma</keyword>
	<keyword>extraocular retinoblastoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent retinoblastoma</keyword>
</DOC>